Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.22 ▼ -0.01
(-0.24%)
MKT CAP: $1.38B • VOL: 2.06M
52W L $3 52W H $7
TSHA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.8M | $8.3M | $15.5M |
| YoY Revenue Growth % | +17.3% | -46.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$110.5M | -$91.5M | -$72.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$109.0M | -$89.3M | -$111.6M |
| EBITDA (Normalized) | -$109.9M | -$91.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$93.1M | -$81.2M | -$73.0M |
| Capital Expenditures (CapEx) | $738.0K | $374.0K | — |
| Free Cash Flow (FCF) | -$93.8M | -$81.6M | -$73.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $319.8M | $139.0M | — |
| Total Debt (Short + Long Term) | $50.1M | $43.9M | — |
| Total Stockholders' Equity | $246.9M | $71.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TSHA.